The rate of major adverse cardiovascular events was not significantly lower with bivalirudin than with heparin ( @ % and @ % , respectively ; relative risk , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ) , nor was the rate of net adverse clinical events ( @ % and @ % , respectively ; relative risk , @ ; @ % CI , @ to @ ; P = @ ) .